ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: efficacy and safety results

被引：0
|
作者：
Strober, B. [1 ]
Crowley, J. [2 ]
Yamauchi, P. [3 ,4 ,5 ]
Yoo, S. [6 ]
Gu, Y. [6 ]
Valdes, J. [6 ]
机构：
[1] NYU, Sch Med, Dept Dermatol, New York, NY USA
[2] Bakersfield Dermatol, Bakersfield, CA USA
[3] Inst Dermatol, Santa Monica, CA USA
[4] Skin Care Ctr Inc, Santa Monica, CA USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P023
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [1] ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results
    Strober, Bruce
    Crowley, Jeffrey
    Valdes, Joaquin
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB155 - AB155
  • [2] Efficacy and safety results of ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Gottlieb, Alice
    Leonardi, Craig
    Valdes, Joaquin
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB159 - AB159
  • [3] Efficacy and safety results of ABT-874 vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Menter, A.
    Gottlieb, A.
    Leonardi, C.
    Kerdel, F.
    Yoo, S.
    Gu, Y.
    Valdes, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 31 - 32
  • [4] Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis
    Reich, K.
    Valdes, J.
    Langley, R.
    Yoo, S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB147 - AB147
  • [5] Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo
    Crowley, Jeffrey
    Yang, Hongbo
    Sundaram, Murali
    Mulani, Parvez
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB160 - AB160
  • [6] Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis
    Kimball, Alexa B.
    Gordon, Kenneth B.
    Langley, Richard G.
    Menter, Alan
    Chartash, Elliot K.
    Valdes, Joaquin
    ARCHIVES OF DERMATOLOGY, 2008, 144 (02) : 200 - 207
  • [7] Efficacy and safety results of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Menter, A.
    Gottlieb, A.
    Leonardi, C.
    Kerdel, F.
    Gu, Y.
    Valdes, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 38 - 39
  • [8] Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Gottlieb, A. B.
    Leonardi, C.
    Kerdel, F.
    Mehlis, S.
    Olds, M.
    Williams, D. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (03) : 652 - 660
  • [9] Efficacy and safety results from a phase iii, randomized controlled trial comparing two dosing regimens of abt-874 to placebo in patients with moderate to severe psoriasis
    Gordon, K.
    Langley, R.
    Gottlieb, A.
    Papp, K.
    Menter, A.
    Krueger, G.
    Strober, B.
    Gu, Y.
    Valdes, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 30 - 31
  • [10] Efficacy and safety of etanercept in moderate to severe plaque psoriasis
    Tunca, M.
    Koc, E.
    Akar, A.
    Kurumlu, Z.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 53 - 53
12345